Abstract: Objective To explore the effects of combined Olmesartan on cardiac function, inflammatory factors, and left ventricular diastolic function in patients with chronic stable heart failure. Methods The 80 chronic stable heart failure patients treated in Fufeng County People's Hospital from June 2020 to January 2022 were divided into the study group (n=40, adding Olmesartan based on the control group) and the control group (n=40, receiving conventional treatment alone). The treatment effect, the left ventricular posterior wall thickness (LVPWD), ventricular septal thickness (LVEDD), inflammatory factor interleukin-23 (IL-23), interleukin-6 (IL-6), myocardial injury-related protein (PTX-3), heart fatty acid binding protein (H-FABP) levels of two groups were compared, and counted the incidence of adverse reactions in the two groups of patients. Results The total treatment response rate of the study group was significantly higher than the control group (P<0.05); there was no significant difference between the LVEF and LVEDD groups in the two groups before the treatment (P>0.05), the LVPWD and LVEDD in the study group were lower than those in the control group (P<0.05); there was no significant difference in the IL-6 and IL-23 levels between the two patient groups before the treatment (P>0.05), IL-6 levels in patients were lower than in the control group, the IL-23 level was higher than that in the control group (P<0.05); there was no significant difference between the groups of PTX-3 and H-FABP levels in the two groups before the treatment (P>0.05), both PTX-3 and H-FABP were lower in the posttreated study group than in the control group (P<0.05); there was no significant difference between the total incidence of adverse reactions in the study group and the control patients (P>0.05). ConclusionOmesartan has a better treatment effect on chronic stable heart failure, compared with traditional therapy, it can better relieve the inflammatory state and myocardial injury of patients, and the treatment safety is also higher.

Key words: olmesartan, chronic stable phase of heart failure, heart function, inflammatory factors, myocardial injury, clinical efficacy